Since nonmyeloablative host conditioning regimens are associated with reduced regimen-related toxicities, advanced age and most comorbid medical conditions are no longer absolute contraindications for allogeneic hematopoietic cell transplantation (HCT). 1 Consequently, patients receiving nonmyeloablative transplants are often taking several nontransplant-related prescription medications and therefore are at a higher risk for drug-drug interactions. We describe a case of an elderly patient who presented with an adverse drug reaction due to an interaction between the immunosuppressive regimen and simvastatin following a nonmyeloablative HCT for advanced stage multiple myeloma.
A 66-year-old male taking simvastatin for a dyslipidemia was diagnosed with stage IIIA IgG kappa multiple myeloma and received 5 months of therapy with thalidomide, dexamethasone, and pamidronate, and had an excellent clinical response with complete resolution of bone pain and a 475% reduction in his M-protein. He received cyclophosphamide (4 gm/m 2 ) and granulocyte-colony stimulating factor (G-CSF) followed by apheresis of blood mononuclear cells with cryopreservation of the unmanipulated product. He was infused with his autologous product (CD34 þ cell dose ¼ 4.9 Â 10 6 /kg) after conditioning with melphalan (200 mg/m 2 ), and had an unremarkable medical course with an absolute neutrophil count recovery (41500/ml) by day 12 after transplantation. At 75 days after his autologous transplant, he received nonmyeloablative low-dose total body irradiation (TBI), 200 cGy in a single fraction, followed by infusion of G-CSF-mobilized blood mononuclear cells from his HLA-compatible 64-year-old healthy brother. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine dose adjusted for trough levels of 400-600 ng/ml for the first 56 days followed by gradual tapering until discontinuation by 6 months after transplantation, and mycophenalate mofetil (MMF) 15 mg/kg orally twice daily for 28 days after transplantation. At 22 days after transplantation, the patient developed bilateral lower extremity weakness that progressed over 3 days to the extent that he was no longer able to bear weight and ambulate. The only other noteworthy complaint was constant aching in his thighs. He denied any fever, back pain, weakness of his upper extremities, loss of sensation in his lower extremities or perineum, bowel incontinence, or urinary retention. His medications included simvastatin 80 mg daily, cyclosporine and MMF as above, nifedipine for hypertension, levothyroxine for hypothyroidism, and glyburide for non-insulin-dependent diabetes mellitus. On examination, the patient appeared well with normal vital signs. The relevant findings were no neurologic deficits in the upper extremities but muscle strength was 1/5 in the hip flexors bilaterally, 2/5 for bilateral knee flexion and extension, with intact strength throughout the remainder of the distal lower extremities. Sensation in the lower extremities and perineum were intact. Rectal tone was normal. Palpation of the spine revealed no tenderness, but palpation of bilateral quadriceps muscles elicited pain. The remainder of the examination was unremarkable. Laboratory evaluation revealed a urine dipstick with 3 þ blood, but no red cells on microscopy, an elevated serum creatinine of 2.0 mg/dl, AST 555 U/l, ALT 274 U/l, and a total creatinine kinase of 29 253 U/l. The remainder of the laboratory test results was unremarkable. Magnetic resonance imaging showed no evidence of spinal cord compression. Electromyography studies showed profuse spontaneous activity with myopathic abnormalities of motor unit action potential in multiple lower extremity muscle groups. Following a presumed diagnosis of statincyclosporine-induced rhabdomyolysis, the patient was hydrated, and simvastatin and cyclosporine were discontinued. The serum creatinine returned to baseline within 7 days and the creatinine kinase normalized within 14 days. The patient was discharged to home after 14 days in the hospital as he had recovered the ability to ambulate. Medications at discharge included tacrolimus for GVHD prophylaxis and gemfibrozil for treatment of hyperlipidemia. By 2 months after discharge, he had recovered to his baseline functional status.
Elderly patients receiving an allogeneic HCT are at a higher risk for drug-drug interactions than younger patients. Older patients typically have comorbid medical conditions resulting in the use of a large number of nontransplant-related drugs during their treatment. 2 One study of cancer patients in the elderly reported that the mean number of comorbid medical conditions per patient increased from 2.9 for patients aged 60-65 years to 3.6 in those aged 65-70 years. 3 The majority (78%) of the elderly patient population was taking prescription medication and 39% were taking five or more drugs. 3 Renal elimination and liver metabolism of drugs are impaired with aging physiology, further precipitating drug-drug interactions. 4 HMG-CoA reductase inhibitors ('statins') are a cornerstone in the treatment of dyslipidemias, a common medical condition. These medications as monotherapy or as combination therapy are associated with a spectrum of muscle disorders ranging from (1) myopathy, defined as any muscle complaint; (2) myalgias, defined as muscle complaints with a normal CK; (3) myositis, defined as muscle symptoms with CK elevation; and (4) rhabdomyolysis, defined as muscle symptoms associated with an elevation of creatinine and elevation of creatinine kinase greater than 10 times the upper limit of normal. 5 Rhabdomyolysis occurring in solid organ transplant recipients after the concomitant use of cyclosporine and a statin have been described. 6 In patients treated with cyclosporine and a statin, the risk of myositis has been shown to be as high as 13-30% in studies of lovastatin at a dose of 40-80 mg daily 7 and simvastatin at a dose of 20 mg daily. 8 Cyclosporine and simvastatin are metabolized in the liver and are substrates for the same cytochrome P450 (CYP) isoenzyme, CYP3A4. 5 The coadministration of these medications results in an increase in statin blood levels which correlates with a higher risk of muscle disorders. High statin blood levels are thought to inhibit chloride channels in myocytes, leading to unopposed muscle contraction and resulting in rhabdomyolysis. 5 High statin blood levels also lead to depletion of mevalonic acid and coenzyme Q10, which are metabolic intermediates in cholesterol synthesis. 5 A reduction in coenzyme Q10 results in decreased oxidative phosphorylation and impaired cellular respiration in muscle. Mitochondrial dysfunction has been demonstrated in studies of patients with statininduced myopathy. Muscle pathology in such cases has revealed ragged red fibers suggesting a mitochondrial myopathy. 5 Not all statins have the same risk of inducing muscle disorders when coadministered with cyclosporine. As pravastatin is not metabolized by the P450 isoenzyme system, it is the only statin approved by the United States Food and Drug Administration (FDA) for combination therapy with cyclosporine. 9 However, reports from the FDA have confirmed a risk of myopathy when pravastatin is combined with cyclosporine, suggesting a drug-drug interaction beyond the P450 metabolism. 9 This report underscores the potentially serious consequences when cyclosporine and statins are coadministered. Patients receiving nonmyeloablative conditioning regimens for allogeneic HCT are at risk for drug-drug interactions as older individuals, and those with comorbid medical conditions often are taking multiple nontransplant-related prescription medications. Considering that 450% of all prescription medications are substrates, inducers, or inhibitors of the CYP3A4 isoenzyme, 3 the same enzyme metabolizing cyclosporine and tacrolimus, the risk of drugdrug interactions during the peritransplant period should be anticipated.
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